Concepedia

Tanvi H. Visal

TH

Statistics

Publications

4

Citations

1.3K

H-Index

4

Active since

2019

Affiliations

Dana-Farber Cancer Institute(Current)

Broad Institute

Brigham and Women's Hospital

The University of Texas MD Anderson Cancer Center

Tanvi H. Visal is an author at Dana-Farber Cancer Institute specializing in oncology, medicine, and molecular oncology.

Publications per year

2019–2023

4

Publications

4

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira et al. · Cancer Discovery · 2019 · 720 citations · Full text

Medicine, Immunology, Oncology +17

A proteogenomic portrait of lung squamous cell carcinoma

Shankha Satpathy, Karsten Krug, Pierre M. Jean Beltran et al. · Cell · 2021 · 387 citations · Full text

Medicine, Cancer Biology, Oncology +17

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

Liam Cornell, Seth A. Wander, Tanvi H. Visal et al. · Cell Reports · 2019 · 140 citations · Full text

Medicine, Oncology, Pharmacology +14

Stabilizing vimentin phosphorylation inhibits stem-like cell properties and metastasis of hybrid epithelial/mesenchymal carcinomas

Nick A. Kuburich, Petra den Hollander, María Castañeda et al. · Cell Reports · 2023 · 22 citations · Full text

Medicine, Cell Biology, Oncology +14

1–4 of 4